TY - JOUR
T1 - Bringing the Next Generation of Food Allergy Diagnostics into the Clinic
AU - Santos, Alexandra F.
AU - Kulis, Michael D.
AU - Sampson, Hugh A.
N1 - Funding Information:
Conflicts of interest: A.F. Santos reports grants and personal fees from Medical Research Council (MR/M008517/1; MR/T032081/1); grants from Food Allergy Research and Education, Asthma UK, and the National Institute for Health Research through the Biomedical Research Centre award to Guy's and St Thomas' National Health Service Foundation Trust and the Immune Tolerance Network/National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH); consultancy fees from Thermo Scientific, Nutricia, Infomed, Novartis, and Buhlmann; consultancy fees from Allergy Therapeutics, Novartis, Iggenix, and Stallergenes; as well as research support from Buhlmann and Thermo Scientific through a collaboration agreement with King's College London. M.D. Kulis reports funding through NIH-NIAID and the Department of Defense and consultancy fees from Ukko. H.A. Sampson receives funding to his institution for grants from NIH/NIAID and has received consulting fees from DBV Technologies, S.A., N-Fold, LLC, and Siolta Therapeutic, Inc, and stock options from DBV Technologies and N-Fold Therapeutics.
Funding Information:
Conflicts of interest: A.F. Santos reports grants and personal fees from Medical Research Council ( MR/M008517/1 ; MR/T032081/1 ); grants from Food Allergy Research and Education , Asthma UK , and the National Institute for Health Research through the Biomedical Research Centre award to Guy's and St Thomas' National Health Service Foundation Trust and the Immune Tolerance Network / National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH); consultancy fees from Thermo Scientific, Nutricia, Infomed, Novartis, and Buhlmann; consultancy fees from Allergy Therapeutics, Novartis, Iggenix, and Stallergenes; as well as research support from Buhlmann and Thermo Scientific through a collaboration agreement with King's College London. M.D. Kulis reports funding through NIH-NIAID and the Department of Defense and consultancy fees from Ukko. H.A. Sampson receives funding to his institution for grants from NIH / NIAID and has received consulting fees from DBV Technologies, S.A., N-Fold, LLC, and Siolta Therapeutic, Inc, and stock options from DBV Technologies and N-Fold Therapeutics.
Publisher Copyright:
© 2021 The Authors
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2022/1
Y1 - 2022/1
N2 - Food allergy diagnosis has a massive impact on the lives of patients and their families. Despite recent developments with specific IgE to component allergens, a significant proportion of patients assessed for possible food allergy require oral food challenge to ensure an accurate diagnosis. More precise diagnostic methods are required to reduce the need for oral food challenges. Bead-based epitope assays and cellular tests, such as basophil activation and mast cell tests are the most novel and promising tests on the horizon. There is a pathway to pursue to enable their incorporation in clinical practice, including standardization, technical validation, clinical validation, external validation, overcoming practical and logistical issues, and regulatory approval. Valuable clinical application of these tests goes beyond diagnosis and includes risk assessment to identify allergic patients who are most sensitive and at risk for severe allergic reactions, and to define prognosis and assess clinical response to immunomodulatory treatments.
AB - Food allergy diagnosis has a massive impact on the lives of patients and their families. Despite recent developments with specific IgE to component allergens, a significant proportion of patients assessed for possible food allergy require oral food challenge to ensure an accurate diagnosis. More precise diagnostic methods are required to reduce the need for oral food challenges. Bead-based epitope assays and cellular tests, such as basophil activation and mast cell tests are the most novel and promising tests on the horizon. There is a pathway to pursue to enable their incorporation in clinical practice, including standardization, technical validation, clinical validation, external validation, overcoming practical and logistical issues, and regulatory approval. Valuable clinical application of these tests goes beyond diagnosis and includes risk assessment to identify allergic patients who are most sensitive and at risk for severe allergic reactions, and to define prognosis and assess clinical response to immunomodulatory treatments.
KW - Basophil activation test
KW - Diagnosis
KW - Epitope mapping
KW - Food allergy
KW - Mast cell activation test
UR - http://www.scopus.com/inward/record.url?scp=85115809740&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2021.09.009
DO - 10.1016/j.jaip.2021.09.009
M3 - Article
AN - SCOPUS:85115809740
SN - 2213-2198
VL - 10
SP - 1
EP - 9
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 1
ER -